Globus Medical stock is down today on an unexpectedly soft Q1 amid an earlier-than-planned integration with recently acquired ...

Q1 2025 Management View CEO Dan Scavilla noted that Q1 revenue was $598 million, with a slight decline of 0.8% year-over-year on a constant currency basis. Issues impacting sales included temporary ...

(NYSE: NYSE:NVRO), a global medical device firm specializing in chronic pain treatment, for approximately $250 million in cash. The acquisition, announced today, will see Globus Medical buy all ...

Globus Medical, Inc. (NYSE:GMED) just released its latest quarterly report and things are not looking great. It wasn't a great result overall - while revenue fell marginally short of analyst ...

Globus Medical, Inc., a medical device company ... such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral ...

Globus Medical, Inc.’s GMED share price has dipped by 21.03%, which has investors questioning if this is right time to buy.

expanding Globus Medical's reach into the musculoskeletal market, particularly in neuromodulation technology and chronic pain treatment solutions. Management reaffirmed 2025 revenue guidance of $2 ...